The U.S. FDA accepted a supplemental New Drug Application for Jardiance based on cardiovascular risk reduction data from the landmark EMPA-REG OUTCOME® trial.
Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada
Eli Lilly and Company announced today that the U.S. FDA has approved Taltz® injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Novartis announced that the United States FDA approved Afinitor® tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.
Alexion Pharmaceuticals, Inc announced that Japan’s Ministry of Health, Labour and Welfare has approved Kanuma for the treatment of patients of all ages in Japan with lysosomal acid lipase deficiency.